Abstract
The heart is the first organ to develop in the mammalian embryo and its architecture is dependent on the spatial organisation of diverse cell types and morphogenetic transformations shaped by biophysical forces. Cardiac remodelling occurs in the mature heart and is a cascade of adaptations in response to stress that are primed in early life. A key question remains as to the processes that regulate the geometry and motion of the heart, and how it adapts to stress. Here we performed a spatially-resolved genome-wide association study of three-dimensional cardiac traits in 47,549 participants of UK Biobank. We found 42 loci associated with cardiac structure and contractility many of which reveal patterns of spatial organisation in the heart. Newly discovered loci relate to pathways implicated in cardiomyocyte differentiation and chamber development as well as those linked to cardiomyopathies. These findings provide a comprehensive description of the pathways that orchestrate heart development and mechanisms that regulate adaptation in health and disease.
Competing Interest Statement
D.P.OR has consulted for Bayer AG and Bristol Myers-Squibb. J.S.W. has consulted for MyoKardia, Inc., Pfizer, Foresite Labs, Health Lumen, and Tenaya Therapeutics, and has received research support from Bristol Myers-Squibb. K.A.McG has consulted for Checkpoint Capital LP. S.L.Z has consulted for Health Lumen. None of these activities are directly related to the work presented here. All other authors have nothing to disclose
Funding Statement
This work was supported by the British Heart Foundation, UK [FS/IPBSRF/22/27059, RG/19/6/34387, RE/18/4/34215, CH/P/23/80008, RG/F/22/110078, FS/CRTF/21/24183, RG/F/22/110078, RE/24/130023, SP/17/11/32885, Medical Research Council, UK [MC-A658-5TY00, MC_UP_1605/13], Engineering and Physical Sciences Research Council, UK [EP/W01842X/1], Sir Jules Thorn Charitable Trust, UK [21JTA], and the NIHR Imperial College Biomedical Research Centre, UK and the NIHR University College London Biomedical Research Centre, UK. The views expressed in this work are those of the authors and not necessarily those of the funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK National Research Ethics Service gave ethical approval for the UK Biobank study (11/NW/0382).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
All raw and derived data in this study are available from UK Biobank (http://www.ukbiobank.ac.uk/), conducted under application number 40616. GWAS summary level data are publicly available through the GWAS catalogue (https://www.ebi.ac.uk/gwas/).For colocalization analyses, we used the unfiltered eQTL results from eQTL Catalogue (https://www.ebi.ac.uk/eqtl/) and the Genotype-Tissue Expression (GTEx) Portal v.8 (https://gtexportal.org/home/).
